

## 7. Registration Applications

Nil items

## 8. Regulatory Reforms

Nil items

## 9. Adverse Drug Reactions associated with complementary medicines.

### 9.1 ADRs associated with complementary medicines from 1 August to 31 October 2010

#### Outcome

ACCM noted the adverse events reported for complementary medicines from 1 August 2010 to 31 October 2010

## 10. Matters Referred from within TGA

### 10.1 Krill oil compositional guidelines

A TGA Officer introduced this item, reminding Members that *Euphausia superba* (krill) oil was approved by the OCM for use as an ingredient in listed medicines in September 2007. As part of the application, a draft compositional guideline (CG) was provided for the substance and was subsequently published for comment on the TGA website.

During the comment period for the draft CG, submissions were received by the OCM. These submissions noted the restrictive nature of many of the specifications included in the draft CG and raised concerns that their essentially similar oils would not meet these limits. A number of technical reports were submitted in order to support the case for widening limits on various constituents of krill oil.

As a result of the new data being submitted, the OCM investigated the possibility of a single CG being sufficient to control different types of solvent-extracted krill oil. Initial concerns were raised that appropriate justifications to assure both quality and safety would need to be provided for individual solvent processes. However, having reviewed the additional data, including expert safety reports, and in particular the European Commission decision to recognise two types of solvent-extracted krill oil (one the subject of original CG) as "substantially equivalent", the OCM decided that a single CG would satisfactorily control the quality and safety of various types of solvent-extracted krill oils.

An update of the original draft CG was prepared and published for further comment. During the comment period for the revised CG, which incorporated wider limits for some specification parameters, an applicant submitted a counter-argument for retaining the original limits. The applicant argued that the revised CG allows the use of various types of solvent-extracted krill oil which have not been assessed by the OCM for safety and efficacy. The submission also claimed that the USP was working on a monograph for krill oil as a dietary supplement, which, when published, would become a default quality standard, making the TGA CG obsolete. However, the TGA Officer advised ACCM that if the USP includes a monograph for krill oil, the OCM considers it likely that it would provide broader specification limits than the current TGA CG, thus capturing the various types of krill oil available.

Formatted: Strikethrough

The principle changes included in the revised CG were summarised for ACCM as follows:

- Limits for oxidation markers have been extended, as both hot and cold extractions using various *British Pharmacopoeia* (BP)-compliant organic solvents have been allowed. It should be noted however, that these remain under the values stipulated in the BP and USP monographs for similar ingredients (e.g. fish oil).
- There are increased limits for content of copper and alpha-tocopherol, but these do not result in significant changes to the total daily intake, considering the recommended daily intakes for these components.
- Maximum limits of the main active components remain unchanged, but lower minimum limits allow compliance for a range of oils. As such, the safety profile of the krill oil is not affected.
- Removal of the separate value for esterified astaxanthin, in favour of retention of a single value for astaxanthin diol, is made on the basis of the latter being a more analytically valid parameter. This change is not considered to affect the quality of the substance.

ACCM was asked to consider the existing CG and the revised draft CG for krill oil; provide advice on the validity of the arguments for and against widening the specifications; and provide an opinion as to whether the OCM revised CG adequately controls the quality and safety of various types of solvent- extracted krill oil.

#### **Discussion**

##### Legal standing of compositional guidelines

Members noted that compositional guidelines have no legal underpinning and are therefore not enforceable. Krill oil is an approved Listable substance, irrespective of whether the substance complies with the compositional guideline or not. That is, there is nothing to stop a sponsor from including in their medicine a krill oil that is not compliant with the compositional guideline.

Members agreed that the role of compositional guidelines should be reviewed and ideally, compositional guidelines should be monographs and legally enforceable.

While acknowledging that compositional guidelines are not enforceable, a TGA Officer stated that any requirements can be included in the definition of the ingredient and, therefore, can be enforced as a condition of Listing.

Members considered that the current issue was in essence, an issue in relation to a sponsor's proprietary rights to the ingredient.

##### Consideration of efficacy and dosage

Members discussed that when assessing a product, the Committee could consider dosage and efficacy of the medicine but for a new Listable substance efficacy is not evaluated, other than establishing that the substance is an active ingredient.

##### Differences in the two compositional guidelines

Members noted the variation in the two TGA Krill oil CGs, noting that the original CG contained significantly higher amounts of essential fatty acids and much broader allowances for the active component, astaxanthin. Members debated if the broadening of the criteria in the CG was a compromise on the safety of the substance. It was agreed that while there was no real safety

concern, there was a difference in quality between the substances, but whether this resulted in two different ingredients was questionable. Members considered that the two materials were essentially the same ingredient, just different classes or grades. As one material has more biological activity than the other, this would have to be reflected in different recommended dosages for the two materials, which could be confusing for consumers.

Members questioned when it was appropriate to separate an ingredient into two different ingredients. A comparison was made to fish oil, with Members noting that there are many different compositional guidelines for fish oil and questioning whether this could be the same for krill oil. However, little advantage could be seen for this, and Members considered it would cause considerable consumer confusion.

#### Natural substance variation and differentiation

Members discussed that natural products were inherently variable (e.g. analogues, different processing, natural variation) and that different solvents would create different preparations e.g. acetone extracts fatty acids and would result in a different chemical profile to an alcoholic extract.

It was noted that this was the same for herbal ingredients, where use of different plant parts or preparations resulted in different ingredients. Members questioned how herbal ingredients were differentiated. A TGA Officer responded that the complete herbal name consisted of the botanical name plus the plant part plus the preparation. Members questioned if this could be applied to differentiate the different types of krill oil, but again, Members could see little advantage in this and considered it would cause considerable consumer confusion.

#### Potential USP monograph

Members noted that in the event that a monograph was included in the USP, this would be the standard adopted by the TGA and would override any compositional guidelines for the material.

#### Conclusion

Members considered that while the two compositional guidelines for krill oil resulted in two substances of differing quality, there were no safety concerns for either material. While the Committee considered allowing two compositional guidelines for krill oil, it was agreed that there would be little advantage in this and it would be confusing for consumers. Members agreed that the broader compositional guideline for Krill oil should be adopted and any differences in material quality would be reflected in different product dosages.

#### **Recommendation 4.2**

ACCM recommends to the TGA that the revised compositional guideline, which includes broader specifications, be adopted to control quality and safety of all solvent-extracted krill oils.

#### **Outcome**

In making the above recommendation:

- ACCM recognises that krill oil is an approved listable substance irrespective of whether the substance complies with the compositional guideline.
- Based on the presented data ACCM identified no safety concerns in either of the two compositional guidelines, providing the krill oil is identified and the solvents used are compliant with the requirements in the *British Pharmacopoeia*.
- ACCM recognises that different raw material processing methods may result in different constituent profiles in the final material. However, this is not uncommon in natural substances and is therefore not a strong argument for the existence of more than one compositional guideline. Further, ACCM noted that variations in the active constituent profile may be reflected in the final dosage instructions for the therapeutic product.
- Finally, ACCM also notes the possibility of a relevant monograph being included in a TGA recognised standard in the future and that this may impact on the need for a krill oil compositional guideline.

## **10.2 Summary of ACCM considerations to date**

### **Outcome**

ACCM noted the consolidated list of ACCM items considered, recommendations and action items from 2010.

## **11.1 Advisory Committee on Non-prescription medicines August 2010 minutes**

### **Outcome**

Members noted the Advisory Committee on Non-prescription medicines August 2010 minutes.

## **11.2 Advisory Committee on the Safety of Medicines 3rd meeting minutes**

### **Outcome**

Members noted the Advisory Committee on the Safety of Medicines 3rd meeting minutes.

## **11.3 Advisory Committee on the Safety of Medicines 4th meeting minutes**

### **Outcome**

Members noted the Advisory Committee on the Safety of Medicines 4th meeting minutes.

## **11.4 Medicines Safety Update No 5 bulletin**

### **Outcome**

Members noted the Medicines Safety Update No 5 bulletin.